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blood cells 4 800 000 mm−3 (n.v. 4 500 000–6 000 000), hemoglobin 
14.4 g dl−1 (n.v. 13.5–17.5), hematocrit 42.5% (n.v. 41–50), fibrinogen 
362  mg dl−1 (n.v. 200–400), prothrombin time 15 s (n.v. 16–20), 
international normalized ratio 1.07 (n.v. 0.85–1.25), and activated partial 
thromboplastin time 1.13 s (n.v. 0.82–1.24).
Suspecting DVT, a lower limbs Doppler ultrasonography of the 
deep venous system was performed, showing a partial obstruction with 
internal thrombus from the left popliteal vein to the left external iliac vein.
After diagnosis of DVT, a thrombophilia screening was performed, 
revealing an increased activity of clotting factor VIII  (Table  1). 
Testosterone levels were not measured in the absence of signs and 
symptoms suggestive of testosterone deficiency.5
Anticoagulant treatment with low‑molecular‑weight heparin 
(enoxaparin) was initiated along with warfarin for 5 days. After the 
therapeutic range was reached (i.e. prothrombin time 2–3 by international 
normalized ratio), treatment was continued with warfarin alone. On 
discharge, D‑dimer levels were reduced  (6.96 µg ml−1) and Doppler 
ultrasonography of the deep venous iliac – femoral – popliteal system 
showed signs of initial revascularization and thrombus dissolution.
Among different treatments proposed for idiopathic male infertility, 
anti‑estrogens, like tamoxifen, may be taken into account. Tamoxifen 
seems to have a positive effect on sperm count and concentration in 
eugonadal patients, but it does not improve other semen parameters 
such as motility, morphology, and viability probably due to its effects 
on the first steps of spermatogenesis.6 Literature data suggest a better 
effect of tamoxifen in patients with low FSH levels, suggesting the 
need for a well‑functioning hypothalamic‑pituitary‑gonadal axis. 
On the other hand, oxidative stress has well‑recognized deleterious 
effects on sperm function. Estrogens have been shown to modulate 
the antioxidant system in human semen, and this provides a further 
rationale for antiestrogen administration in male infertility.7
Noteworthy, tamoxifen, which is widely used as adjuvant therapy 
for breast cancer in women, increases the risk of thromboembolic 
events.8 To the best of our knowledge, no known clotting abnormalities 
in males treated with tamoxifen for idiopathic infertility have been 
reported, also because it is used as an off‑label treatment and rigorous 
safety analyses are lacking.
The potential mechanism for the procoagulant effect of tamoxifen 
has not been fully elucidated, although a reduction in antithrombin III 
and protein C levels or an APC resistance phenotype have been reported.9
We conclude that immobilization due to the recent long haul trips 
along with the use of tamoxifen‑induced a hypercoagulable state, 
thus increasing the risk of thrombosis in this patient. We observed 
Dear Editor,
We present here a case of idiopathic male infertility who developed 
deep vein thrombosis (DVT) with the use of tamoxifen, a selective 
estrogen receptor modulator, probably through a hypercoagulable state.
A selective estrogen receptor modulator (SERM) is a compound 
that can act as an estrogen agonist or antagonist, depending on the 
specific target tissue. At present, four SERMs are approved for clinical 
use: clomiphene, raloxifene, tamoxifen, and toremifene. In women, 
SERMs are widely used as adjuvant therapy for breast cancer. SERMs 
in males have been suggested as an empiric treatment for idiopathic 
infertility, but relatively few studies are currently available.1
Tamoxifen administration in males indirectly stimulates follicle 
stimulating hormone (FSH) and luteinizing hormone (LH) secretion 
by blocking estrogen receptors in the hypothalamus and pituitary gland, 
thus increasing the hypothalamic release of gonadotrophic releasing 
hormone (GnRH). The major effect of tamoxifen administration is the 
stimulation of Leydig cells to produce testosterone and of Sertoli cells to 
improve the testicular environment for spermatogenesis.2 Noteworthy, 
tamoxifen has also been reported to directly stimulate Leydig cells 
and 5α‑dihydrotestosterone production in seminiferous tubules and 
epididymis.3 Tamoxifen increases the risk of venous thrombosis by 2‑ to 
3‑fold.4 The underlying mechanisms in patients receiving tamoxifen 
have not been completely elucidated yet, although a decrease of several 
coagulation inhibitors has been reported. Tamoxifen‑associated changes 
of the coagulation system differ substantially from estrogen‑induced 
alterations, still it has been hypothesized that tamoxifen also induces 
an activated protein C (APC) resistance phenotype.4
A 36‑year‑old Caucasian male was admitted for severe pain at his 
left lower limb. The patient was alert, fully oriented, and did not have 
fever. His left leg was disproportionately large by inspection, with warm, 
reddened, and edematous skin. The patient had taken tamoxifen 20 mg 
daily for 3 months for idiopathic male infertility in a program of assisted 
reproduction. Moreover, he had a recent history of long haul car and 
train trips. He was normal weight (body mass index, BMI 23.5 kg m−2), 
eugonadal at the beginning of tamoxifen treatment (total testosterone 
4.3 ng ml−1), and a nonsmoker.
Blood tests performed on admission showed coagulation abnormalities, 
but no erythrocytosis nor thrombocytosis: D‑dimer 11.12 µg ml−1 (normal 
values, n.v., <0.8), platelet count 177 000 µl−1 (n.v. 150 000–450 000), red 
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an increase in factor VIII activity which favors the propagation and 
amplification, rather than the initiation, of the coagulation cascade, 
increasing the risk of venous thrombosis.10
Although a single case in not sufficient to state a cause and effect 
relationship between tamoxifen and deep vein thrombosis, clinicians 
should be aware of the possibility of thromboembolic complications 
during tamoxifen treatment in males, even when it is administered 
for short periods of 3–6 months. Other treatments for idiopathic male 
infertility should be considered in male patients with an elevated risk 
of thromboembolism.
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Table 1: Thrombophilia screening results in the patient described in 
the text
Laboratory data Patient's results Normal range
Antithrombin III activity 87% 80–120
Resistance to activated protein C (ratio) 4.00 >2.20
Homocysteine 14.1 μmol l−1 6.8–18.9
Protein C activity 118% 70–130
Protein S activity 120% 65–145
Antibodies anticardiolipin and the lupus 
anticoagulant
Not detected
Factor V Leiden gene mutation (G1691A) Negative
Prothrombin gene mutation (G20210A) Negative
Antibodies β2 glycoprotein 1 Not detected
MTHFR (C677T; A1298C) mutation Negative
Factor VIII activity 201% 60–150
MTHFR: methylenetetrahydrofolate reductase
